Gregory C. Critchfield, M.D., M.S.

Gregory C. Critchfield, M.D., M.S.

DirectoratSera Prognostics· In proxies 2022–2025

Pay in FY2023-15% from the year before · Sera Prognostics stock +374.6% the same year

Gregory C. Critchfield, M.D., M.S. was paid $1.5M in FY2023 (Dec), down 15%. Sera Prognostics stock rose 374.6% that year.

Pay$100 in the stock at the end of FY21 → $87
Pay is from the Summary Compensation Table of each Sera Prognostics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Sera PrognosticsPublic company · 4 yr
    • Director2022 – Present · 4 yrStock in role -73%
  2. BioTrove Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Biocius Life Sciences, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Condor Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Epic Sciences, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Integrated Diagnostics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  7. Lantos TechnologiesPublic company
    • Director? – PresentNo stock prices for these years
  8. Metamark Genetics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  9. Nodality, Inc.Public company
    • Director? – PresentNo stock prices for these years
  10. Saladax Biomedical, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Sera PrognosticsDirector · 13 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?